Fundraising FoxENT Vantage
Austin, US · Founded 2014 · 1 known investors
Find your way into ENT Vantage
Sign up to see every warm intro you have to ENT Vantage
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ENT Vantage team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ENTvantage Dx develops rapid, in-office diagnostic tests for primary care physicians and otolaryngologists to identify the causes of ear, nose, and throat illnesses. The company operates in the in-vitro diagnostics sector serving the medical diagnostics industry.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.3M disclosed across 4 rounds · 2014–2019
▶$515KraisedSep 2019 · 6 investors · Other Health CareRule 506(b)
- Richard HawkinsDirector
- Donald GonzalesDirector
- Joseph S SkrabaExecutive Officer, Director
- John PaulosDirector
- Blobel FriedhelmDirector
- Offering amount
- $1M
- Amount sold
- $515K
- First sale
- Aug 2019
- Incorporated
- Corporation, Texas, 2014
- Federal exemptions
- 06b
▶$3.3MraisedOct 2017 · 45 investors · Other Health CareRule 506(b)
- Joseph S SkrabaExecutive Officer, Director
- Donald GonzalesDirector
- Richard HawkinsDirector
- John PaulosDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- Minimum investment
- $5K
- Proceeds to insiders
- $200K
- First sale
- Oct 2017
- Incorporated
- Corporation, Texas, 2014
- Federal exemptions
- 06b
▶$1.4MraisedNov 2016 · 14 investors · Other Health CareRule 506(b)
- Joseph S SkrabaExecutive Officer, Director
- Richard HawkinsDirector
- John PaulosDirector
- Russell BradleyDirector
- Donald GonzalesDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- Proceeds to insiders
- $200K
- First sale
- Jul 2016
- Incorporated
- Corporation, Texas, 2014
- Federal exemptions
- 06b
▶$1MraisedApr 2015 · 11 investors · Other Health CareRule 506(b)
- Richard J HawkinsDirector
- Joseph S SkrabaExecutive Officer, Director
- Donald GonzalesDirector
- Offering amount
- $1.4M
- Amount sold
- $1M
- Minimum investment
- $10K
- Proceeds to insiders
- $225K
- First sale
- Sep 2014
- Incorporated
- Corporation, Texas, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $762.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does ENT Vantage do?
- ENTvantage Dx develops rapid, in-office diagnostic tests for primary care physicians and otolaryngologists to identify the causes of ear, nose, and throat illnesses. The company operates in the in-vitro diagnostics sector serving the medical diagnostics industry.
- Who are ENT Vantage's investors?
- ENT Vantage's investors include Central Texas Angel Network.
- How much funding has ENT Vantage raised?
- ENT Vantage has disclosed $6.3M raised across 4 rounds.
- Where is ENT Vantage headquartered?
- ENT Vantage is headquartered in Austin, US.